FindTrial
Sign In

Luminity 150 microlitres/ml gas and solvent for dispersion for injection/infusion

DRUG2 trials

Sponsors

Carthera, Carthera, Assistance Publique Hopitaux De Paris

Conditions

First recurrence glioblastomaNewly diagnosed Glioblastoma (IDH wild-type) patients at initial radiological diagnosis eligible for tumor resectionand for the standard of care including concurrent temoradiation followed by adjuvant TMZ with or without Tumor Treating Fields*. (*Tumor Treating Fields is applicable only in participating centers in France)

Phase 2

Multisite open-label randomized phase II clinical trial in newly diagnosed glioblastoma treated by concurrent TemoRadiation and adjuvant temozolomide +/- ultrasound-induced blood brain barrier opening - SonoFIRST
Not yet recruitingCTIS2024-511880-27-00
Assistance Publique Hopitaux De Parisand for the standard of care including concurrent temoradiation followed by adjuvant TMZ with or without Tumor Treating Fields*. (*Tumor Treating Fields is applicable only in participating centers in France), Newly diagnosed Glioblastoma (IDH wild-type) patients at initial radiological diagnosis eligible for tumor resection
Target: 63Updated: 2024-12-05

Phase 3

A randomized, open-label, multicentric, two-arm pivotal trial of SonoCloud-9 combined with carboplatin (CBDCA) vs standard of care lomustine (CCNU) or temozolomide (TMZ) in patients undergoing planned resection for first recurrence glioblastoma
SuspendedCTIS2023-505829-14-00
Carthera, CartheraFirst recurrence glioblastoma
Start: 2023-12-22Target: 289Updated: 2025-09-22